Drugs / 177Lu-edotreotide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05918302 | Oct 2023 → Mar 2029 expected | lung neuroendocrine neoplasm, thymus neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Recruiting | No outcome recorded |
| Phase 3 | NCT04919226 | Dec 2021 → Jun 2027 expected | neuroendocrine neoplasm | ITM Solucin GmbH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03049189 | Feb 2017 → Nov 2024 overdue | neuroendocrine neoplasm | ITM Solucin GmbH | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-edotreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05918302 ↗ |
| Known as | (177)Lutetium[Lu]-edotreotide | “A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of...” PMID 40186126 ↗ Apr 2025 |
| Modality | Peptide | “Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide” NCT04919226 ↗ |
| Route | Intravenous | “Route of administration: Slow intravenous infusion/injection (i.v.)” NCT03049189 ↗ |
| Target | SSTR2 | “Retrospective data suggest a potential meaningful benefit of RLT directed to SSTR2 in lung-NET patients.” PMID 40186126 ↗ Apr 2025 |